tert-butyl 2-(pyridin-3-ylmethylene)hydrazinecarboxylate | 392740-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: tert-butyl 2-(pyridin-3-ylmethylene)hydrazinecarboxylate
• 英文别名: tert-Butyl-2-(pyridin-3-ylmethylidene)hydrazinecarboxylate；tert-butyl N-(pyridin-3-ylmethylideneamino)carbamate
• CAS: 392740-65-7
• 化学式: C₁₁H₁₅N₃O₂
• mdl: MFCD03826807
• 分子量: 221.259
• InChiKey: UHKLSNBEFVOBMA-UHFFFAOYSA-N

物化性质

• 熔点：
  150-153 °C
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(pyridin-3-ylmethylene)hydrazinecarboxylate 在 palladium on activated charcoal 4-二甲氨基吡啶 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 18.0h， 生成 tert-butyl N-[[7-chloro-4-oxo-2-(pyrrolidine-1-carbonyl)-1H-quinoline-3-carbonyl]-(pyridin-3-ylmethyl)amino]carbamate
  参考文献：
  名称：

  Synthesis of 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5- b ]quinoline-1,4,10(5 H )-triones as NMDA glycine-site antagonists

  摘要：

  Several members of the 7-chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5-b]quinoline-1,4,10(5H)-triones (2) have been identified as being potent and selective NMDA glycine-site antagonists. Increasing size of the alkyl substituent on the alpha-carbon led to a progressive decrease in binding affinity. Some of these analogues possess improved drug-like properties such as cellular permeability, solubility and oral absorption. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00750-9
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 tert-butyl 2-(pyridin-3-ylmethylene)hydrazinecarboxylate
  参考文献：
  名称：

  新型哒嗪的设计，合成及抗病毒活性

  摘要：

  制备了一系列哒嗪并评估了它们的抗HIV活性。涉及新颖的重排反应的新的合成途径为制备5-羟基哒嗪提供了一种实用的方法。初步的生物测定结果表明，大多数哒嗪具有抗HIV活性。应该提到的是，重排的化合物35和39表现出相对较高的HIV抑制作用。还发现大多数合成的化合物都具有良好的抗TMV活性，其中化合物9在体内显示出相似的抗TMV活性。对商用植物杀病毒核糖蛋白瑞巴韦林具有抗TMV活性。这项工作提供了一种新的有效方法，可以通过合理整合和优化先前报道的抗病毒剂来开发新型多功能抗病毒剂。

  DOI：

  10.1016/j.ejmech.2012.04.020

文献信息

• PYRAZOLE COMPOUNDS
  申请人：FUKUMOTO Shoji

  公开号：US20100094000A1

  公开（公告）日：2010-04-15

  The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineralocorticoid receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of a disease or condition mediated by the mineralocorticoid receptor activation.

  本发明涉及其中每个符号如规范中定义的。该化合物具有优越的矿物皮质激素受体拮抗作用，并可用作通过矿物皮质激素受体激活介导的疾病或病况的预防或治疗剂。
• 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE
  申请人：AYUMI Pharmaceutical Corporation

  公开号：EP3640253A1

  公开（公告）日：2020-04-22

  The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

  本发明的 6H-噻吩并[2,3-e][1,2,4]三唑并[3,4-c][1,2,4]三氮杂卓衍生物或其盐类具有 BRD4 抑制活性，因此可用作药物，特别是用作与 BRD4 相关疾病的预防和/或治疗药物。
• 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative
  申请人：AYUMI PHARMACEUTICAL CORPORATION

  公开号：US11186588B2

  公开（公告）日：2021-11-30

  The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

  本发明的 6H-噻吩并[2,3-e][1,2,4]三唑并[3,4-c][1,2,4]三氮杂卓衍生物或其盐类具有 BRD4 抑制活性，因此可用作药物，特别是用作与 BRD4 相关疾病的预防和/或治疗药物。
• Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists
  作者：Tomoaki Hasui、Norio Ohyabu、Taiichi Ohra、Koji Fuji、Takahiro Sugimoto、Jun Fujimoto、Kouhei Asano、Masato Oosawa、Sachiko Shiotani、Nobuhiro Nishigaki、Keiji Kusumoto、Hideki Matsui、Atsushi Mizukami、Noriyuki Habuka、Satoshi Sogabe、Satoshi Endo、Midori Ono、Christopher S. Siedem、Tony P. Tang、Cassandra Gauthier、Lisa A. De Meese、Steven A. Boyd、Shoji Fukumoto

  DOI：10.1016/j.bmc.2014.07.038

  日期：2014.10

  In the course of our study on selective nonsteroidal mineralocorticoid receptor (MR) antagonists, a series of novel benzoxazine derivatives possessing an azole ring as the core scaffold was designed for the purpose of attenuating the partial agonistic activity of the previously reported dihydropyrrol-2-one derivatives. Screening of alternative azole rings identified 1,3-dimethyl pyrazole 6a as a lead compound with reduced partial agonistic activity. Subsequent replacement of the 1-methyl group of the pyrazole ring with larger lipophilic side chains or polar side chains targeting Arg817 and Gln776 increased MR binding activity while maintaining the agonistic response at the lower level. Among these compounds, 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one (37a) showed highly potent in vitro activity, high selectivity versus other steroid hormone receptors, and good pharmacokinetic profiles. Oral administration of 37a in deoxycorticosterone acetate-salt hypertensive rats showed a significant blood pressure-lowering effect with no signs of antiandrogenic effects. (C) 2014 Elsevier Ltd. All rights reserved.
• EP3640253
  申请人：——

  公开号：——

  公开（公告）日：——